Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 65years) With mCRPC Previously Treated With a Docetaxel-containing Regimen

NCT02961257 is registered in ClinicalTrials.gov with Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie as lead sponsor.

NCT NCT02961257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02961257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 65years) With mCRPC Previously Treated With a Docetaxel-containing Regimen
Lead sponsor
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase
Phase 3
Overall status
Completed
Start date
May 5, 2017
Completion date
December 2, 2021
Enrollment
196 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic